Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects.

@article{Bhavnani2004PharmacokineticsSA,
  title={Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects.},
  author={Sujata M. Bhavnani and Joel S. Owen and Jeffery S. Loutit and Steven B. Porter and Paul G. Ambrose},
  journal={Diagnostic microbiology and infectious disease},
  year={2004},
  volume={50 2},
  pages={95-102}
}
Oritavancin (LY333328 diphosphate) is a novel glycopeptide antimicrobial agent with potent microbiological activity in vitro against Gram-positive bacteria. A single-dose, open-label, noncontrolled, dose-escalation study in 11 healthy human subjects was carried out to evaluate the safety and pharmacokinetics of oritavancin. One subject at each dose level… CONTINUE READING